Francesco Costa

Government, Health and Not for Profit

Biography

Latest publications

ROGNONI C., MILANO C., Heffler E., Bonini M., Brussino L., Carpagnano G. E., Ricciardolo F. L. M., COSTA F., ARMENI P. Economic impact of a more extensive use of FENO testing on the Italian population with asthma Respiratory Research, 2023, vol.24, no. 1
ROGNONI C., FALIVENA C., COSTA F., ARMENI P. Cost-Utility Analysis of Esketamine for Patients with Treatment-Resistant Depression in Italy PharmacoEconomics, 2023, vol.41, pp.209–225
FEDERICI C. B., ROGNONI C., COSTA F., ARMENI P., Crovato E., Bellucci S. Use of Resource Modeling to Quantify the Organizational Impact of Subcutaneous Formulations for the Treatment of Oncologic Patients: The Case of Daratumumab in Multiple Myeloma Clinical Therapeutics, 2022, vol.44, no. 11, pp.1480-1493
BORSOI L., ARMENI P., Donin G., COSTA F., Ferini-Strambi L. The invisible costs of obstructive sleep apnea (OSA): Systematic review and cost-of-illness analysis Plos One, 2022, vol.17, no. 5, pp.e0268677
JOMMI C., ARMENI P., COSTA F., ALBERTI C., BANDELLO F., BORDONARO R., CAPRODOSSI A., DI MAIO M., GAUDIOSO A., GIULIANI G., LANGELLA R., MARATA A. M., PATARNELLO F., PINTO C., RASI G., VILLA F. Programmi di early access dei farmaci e managed entry agreement in Italia: i risultati di un Focus Group (programmi di early access e managed entry agreement) Recenti Progressi in Medicina, 2021, vol.112, no. 11, pp.749-756
ARMENI P., BERTOLANI A., BORSOI L., COSTA F. La spesa sanitaria: composizione ed evoluzione in Rapporto OASI 2021 CERGAS (Eds),Egea, chap. 3, pp.117-173, 2021